The FDA has approved ruxolitinib cream 1.5% for the short-term and non-continuous chronic treatment of non-immunocompromised children 2-11 years old with mild-to-moderate atopic dermatitis (AD) whose ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. AD affected more than 35% body surface area of study ...

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard ...

Twice-daily application of 1.5% ruxolitinib cream was found to be effective in children and adolescents with atopic dermatitis and vitiligo. Children and adolescents with atopic dermatitis (AD) and ...

The efficacy of ruxolitinib cream in pediatric patients shows that nonsteroidal management of atopic dermatitis is feasible, said Lawrence Eichenfield, MD, chief of pediatric and adolescent ...

The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date for the topical formulation of the JAK inhibitor ruxolitinib as a treatment of atopic dermatitis (AD) in children aged 2-11 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Body surface area percentages fell from 9.6% to 2.9% at ...

Add Yahoo as a preferred source to see more of our stories on Google. The double-blind Incyte has announced results from the Phase IIIb TRuE-AD4 trial of Opzelura (ruxolitinib cream) for adults with ...

Treatment with ruxolitinib cream resulted in significant disease control over 52 weeks in a subset of children with moderate/more extensive atopic dermatitis (AD) in a randomized trial that evaluated ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application ...

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of ...

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis ...